Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Pivotal Trial of XEN496 in Patients with Epileptic Encephalopathy (KCNQ2-DEE, a severe and rare form of pediatric epilepsy)

Trial Profile

A Phase 3 Pivotal Trial of XEN496 in Patients with Epileptic Encephalopathy (KCNQ2-DEE, a severe and rare form of pediatric epilepsy)

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 31 Mar 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Retigabine (Primary)
  • Indications Epilepsy
  • Focus Registrational; Therapeutic Use
  • Sponsors Xenon Pharmaceuticals
  • Most Recent Events

    • 31 Mar 2020 According to an Xenon Pharmaceuticals media release, the PK profile observed for XEN496 appears to be comparable to historical PK data for immediate-release ezogabine tablets, with XEN496 showing similar absorption and elimination curves.
    • 31 Mar 2020 According to an Xenon Pharmaceuticals media release, initiation of this study is dependent upon the ability to initiate clinical sites and patient enrollment given the ongoing COVID-19 pandemic.
    • 31 Mar 2020 According to an Xenon Pharmaceuticals media release, data from PK study (700317037) will support this trial.
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top